drugset / Trial / NCT05467995
A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AK111 in subjects with active ankylosing spondylitis.
Timeline
- Start
- 2021-06-02
- Primary completion
- 2022-04-25
- Completion
- 2022-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GUMOKIMAB | Monoclonal antibody | 75 mg | Subcutaneous |
| Subject | GUMOKIMAB | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | GUMOKIMAB | Monoclonal antibody | 300 mg | Subcutaneous |